Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.48 |
| ▸ | PLD2 | O14939 | 1/20 | 0.47 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.46 |
| ▸ | NHERF1 | O14745 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5896655 | 0.88 | KDM4E (0.51) | PLD2PLD1ITGB3ITGA2BNHERF1 | |
| SCHEMBL5680218 | 0.88 | ITGB3 (0.50) | PYGLITGB3ITGA2B | |
| SCHEMBL5896620 | 0.87 | KDM4E (0.50) | PYGLPLD2PLD1ITGB3ITGA2B | |
| SCHEMBL5889537 | 0.86 | KDM4E (0.51) | PLD2PLD1ITGB3ITGA2BNHERF1 | |
| SCHEMBL5889476 | 0.84 | KDM4E (0.61) | ITGB3ITGA2BNHERF1HDAC2KDM4E | |
| SCHEMBL5889592 | 0.83 | ITGB3 (0.50) | PLD2PLD1ITGB3ITGA2BNHERF1 | |
| SCHEMBL5889883 | 0.83 | ITGB3 (0.47) | PLD2PLD1ITGB3ITGA2BNHERF1 | |
| SCHEMBL5896468 | 0.82 | MMP13 (0.46) | PYGLPLD2PLD1NHERF1EGFR | |
| SCHEMBL5677265 | 0.82 | ITGB3 (0.54) | PYGLPLD2PLD1ITGB3ITGA2B | |
| SCHEMBL5897606 | 0.82 | LEF1 (0.50) | PLD2PLD1ITGB3ITGA2BNHERF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7141680-B2 | Aromatic compounds possessing antifungal or antibacterial activity | GENELABS TECHNOLOGIES, INC. | 2006-11-28 | — | — | US | disclosed |
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | SMITHKLINE BEECHAM CORPORATION | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063645-A1 | Novel aromatic compounds possessing antifungal or antibacterial activity | ZC3HAV1, TYR, ZC3HAV1L | PYGL 3811/4885PLD2 4718/4885PLD1 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.